Organometallic Compounds
Organo-Metalloid Compounds
(2,857)
Organolithium
(174)
Organocopper
(166)
Metal Aryls
(119)
Organozinc
(117)
Organoaluminum
(114)
Search Within Results
1,006
–
1,020
of
3,270
results
1,006
![Medchemexpress LLC Silane,[[(1a,3b,5E,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraene-1,3-diyl]bis(oxy)]bi... | 111594-58-2 | 99.61% | C40H72O2Si2 | 500 MG](https://assets.fishersci.com/TFS-Assets/CCG/product-images/default.jpg-250.jpg)
Medchemexpress LLC Silane,[[(1a,3b,5E,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraene-1,3-diyl]bis(oxy)]bi... | 111594-58-2 | 99.61% | C40H72O2Si2 | 500 MG
Silane,[[(1a,3b,5E,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraene-1,3-diyl]bis(oxy)]bis[(1,1-dimethylethyl)dimethyl- is a drug intermediate for synthesis of various active compounds. It is for research use only and not sold to patients.
- Drug intermediate for synthesis of various active compounds.
- For research use only.
- Not sold to patients.
- Appearance: Solid.
- Color: White to off-white.
1,007
1,008
1,009
1,010
1,011
1,012
1,013
1,014
1,015
1,016
1,017
Medchemexpress LLC Dota-eb-tate | 2151063-66-8 | 95.4% | 2329.63 | 500 UG
DOTA-EB-TATE is a peptide drug conjugate (PDC) consisting of an SST peptide derivative, DOTA-octreotate, conjugated to an Evans blue analog (EB). This compound is designed to improve the pharmacokinetics of SSTR2 analogs and reduce PRRT toxicity.
- Composed of an SST peptide derivative, DOTA-octreotate conjugated to an Evans blue analog
- Improves the pharmacokinetics of SSTR2 analogs
- Reduces PRRT toxicity
- Can be used for the synthesis and research of Radionuclide-Drug Conjugates (RDCs)
1,018
1,019
1,020